*Results based on a 3-month before & after study conducted with 36 participants
Causes of an SIBO flare-up include diet, stress, and certain medications
Monique Gary, DO, a breast surgical oncologist at St
The absolute difference in liver fat content [LFC] was 4.7% (95% CI from 6.7 to 2.7), with a relative decrease in LFC from baseline of 35.9% and 28.4% for the two individual dosages ( p 40%, renal death, new onset of macroalbuminuria) strongly favored tirzepatide (HR 0.58, 95% CI from 0.43 to 0.80, p = 0.0008)
Key findings: 12 mg dose: Average weight loss of 24.2% of body weight (approximately 58 lbs for a 240 lb individual) 8 mg dose: Average weight loss of 22.8% 4 mg dose: Average weight loss of 17.0% Placebo: Average weight loss of 2.1% Over 90% of participants receiving the 8 mg or 12 mg dose lost at least 10% of body weight Over 75% of participants at the highest dose lost at least 20% of body weight Significant improvements in waist circumference, blood pressure, and lipid profiles were observed across dose groups Phase 2 Trial in Type 2 Diabetes A separate phase 2 trial evaluated retatrutide in adults with type 2 diabetes and obesity (Rosenstock et al., Lancet , 2023)
